Background
The 6-oxopurine phosphoribosyltransferases have been suggested to be a target for the discovery of new antimalarial drugs. This is because protozoan parasites rely solely on the salvage of purines from their host to make the nucleotides needed for RNA and DNA synthesis and lack the de novo pathway. Acyclic nucleoside phosphonates (ANPs) that contain a 6-oxopurine base are good inhibitors of the Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) 6-oxopurine phosphoribosyltransferases (PRTs) [1] . Chemical modifications based on the crystal structure of 2-(phosphonoethoxy) ethylguanine (PEEG) in complex with human HGPRT have led to the design of new ANPs [2] . These novel compounds contain a second phosphonate group attached to the ANP scaffold [3] .
Results

{[(2-[(Guanine-9Hyl)methyl]propane-1,3-diyl)bis(oxy)]bis
(me thy-lene)} diphosphonic acid exhibited a K i value of 30 nM for human HGPRT and 70 nM for Pf HGXPRT. The crystal structure of this compound in complex with human HGPRT shows that it fills or partially fills three critical locations in the active site: the binding sites of the purine base, the 5'-phosphate group, and pyrophosphate [3] . This is the first HG(X) PRT inhibitor that has been able to achieve this result. Pro-drugs have been synthesized resulting in IC 50 values as low as 3.8 μM for Pf grown in cell culture, which is up to 25-fold lower compared to the parent compounds [3] .
Conclusion
The crystal structure of {[(2-[(Guanine-9Hyl)methyl] propane-1,3-diyl)bis(oxy)]bis(methylene)} diphosphonic acid in complex with human HGPRT provides a template for chemical modifications to increase both potency and selectivity for the parasite enzymes. 
